OBJECTIVE: Primary Sjögren syndrome (pSS) is characterized by T and B cell infiltration of exocrine glands. The cysteine protease cathepsin S (CatS) is crucially involved in MHCII processing and T cell stimulation, and elevated levels have been found in patients with RA, psoriasis and pSS. However, little is known about the functional characteristics and mechanisms of SS-A- and SS-B-specific T cells in pSS patients. We herein investigated the inhibition of CatS activity in different biocompartments of pSS patients including antigen-specific T cell responses. METHODS: Ex vivo CatS activity was assessed in tears, plasma and saliva of 15 pSS patients and 13 healthy controls (HC) and in the presence or absence of the specific CatS inhibitor RO5459072. In addition, antigen (SS-A (60kD), SS-B, influenza H3N2, tetanus toxoid and SEB)-specific T cell responses were examined using ex vivo IFN-γ/IL-17 Dual ELISPOT and Bromdesoxyuridin (BrdU) proliferation assays in the presence or absence of RO5459072. Supernatants were analysed for IL-1β, IL-6, IL-10, TNF-α, IL-21, IL-22 and IL-23, using conventional ELISA. RESULTS: CatS activity was significantly elevated in tear fluid, but not other biocompartments, was inversely associated with exocrinic function in pSS patients and could significantly be suppressed by RO5459072. Moreover, CatS inhibition by RO5459072 led to strong and dose-dependent suppression of SS-A/SS-B-specific T cell effector functions and cytokine secretion by CD14+ monocytes. However, RO5459072 was incapable of suppressing SS-A/SS-B-induced secretion of cytokines in CD14+ monocytes when T cells were absent, confirming a CatS/MHCII-mediated mechanism of suppression. CONCLUSION: CatS activity in tear fluid seems to be a relevant biomarker for pSS disease activity. Conversely, CatS inhibition diminishes T cell and associated monokine responses towards relevant autoantigens in pSS. Thus, CatS inhibition may represent a promising novel treatment strategy in pSS.
OBJECTIVE: Primary Sjögren syndrome (pSS) is characterized by T and B cell infiltration of exocrine glands. The cysteine protease cathepsin S (CatS) is crucially involved in MHCII processing and T cell stimulation, and elevated levels have been found in patients with RA, psoriasis and pSS. However, little is known about the functional characteristics and mechanisms of SS-A- and SS-B-specific T cells in pSSpatients. We herein investigated the inhibition of CatS activity in different biocompartments of pSSpatients including antigen-specific T cell responses. METHODS: Ex vivo CatS activity was assessed in tears, plasma and saliva of 15 pSSpatients and 13 healthy controls (HC) and in the presence or absence of the specific CatS inhibitor RO5459072. In addition, antigen (SS-A (60kD), SS-B, influenza H3N2, tetanus toxoid and SEB)-specific T cell responses were examined using ex vivo IFN-γ/IL-17 Dual ELISPOT and Bromdesoxyuridin (BrdU) proliferation assays in the presence or absence of RO5459072. Supernatants were analysed for IL-1β, IL-6, IL-10, TNF-α, IL-21, IL-22 and IL-23, using conventional ELISA. RESULTS:CatS activity was significantly elevated in tear fluid, but not other biocompartments, was inversely associated with exocrinic function in pSSpatients and could significantly be suppressed by RO5459072. Moreover, CatS inhibition by RO5459072 led to strong and dose-dependent suppression of SS-A/SS-B-specific T cell effector functions and cytokine secretion by CD14+ monocytes. However, RO5459072 was incapable of suppressing SS-A/SS-B-induced secretion of cytokines in CD14+ monocytes when T cells were absent, confirming a CatS/MHCII-mediated mechanism of suppression. CONCLUSION:CatS activity in tear fluid seems to be a relevant biomarker for pSS disease activity. Conversely, CatS inhibition diminishes T cell and associated monokine responses towards relevant autoantigens in pSS. Thus, CatS inhibition may represent a promising novel treatment strategy in pSS.
Authors: D I Mitsias; A G Tzioufas; C Veiopoulou; E Zintzaras; I K Tassios; O Kogopoulou; H M Moutsopoulos; G Thyphronitis Journal: Clin Exp Immunol Date: 2002-06 Impact factor: 4.330
Authors: Srikanth R Janga; Mihir Shah; Yaping Ju; Zhen Meng; Maria C Edman; Sarah F Hamm-Alvarez Journal: Biomarkers Date: 2018-09-12 Impact factor: 2.658
Authors: Sarah F Hamm-Alvarez; Srikanth R Janga; Maria C Edman; Sara Madrigal; Mihir Shah; Starleen E Frousiakis; Kavita Renduchintala; Jay Zhu; Seth Bricel; Kimberly Silka; Dianne Bach; Martin Heur; Stratos Christianakis; Daniel G Arkfeld; John Irvine; Wendy J Mack; William Stohl Journal: Arthritis Rheumatol Date: 2014-07 Impact factor: 10.995
Authors: Caroline H Shiboski; Stephen C Shiboski; Raphaèle Seror; Lindsey A Criswell; Marc Labetoulle; Thomas M Lietman; Astrid Rasmussen; Hal Scofield; Claudio Vitali; Simon J Bowman; Xavier Mariette Journal: Ann Rheum Dis Date: 2016-10-26 Impact factor: 19.103
Authors: Laís Garreto; Sébastien Charneau; Samuel Coelho Mandacaru; Otávio T Nóbrega; Flávia N Motta; Carla N de Araújo; Audrey C Tonet; Flávia M B Modesto; Lilian M Paula; Marcelo Valle de Sousa; Jaime M Santana; Ana Carolina Acevedo; Izabela M D Bastos Journal: Front Immunol Date: 2021-06-17 Impact factor: 7.561
Authors: Nabangshu Das; Nikhil G Menon; Luiz G N de Almeida; Paige S Woods; Miriam L Heynen; Gregory D Jay; Barbara Caffery; Lyndon Jones; Roman Krawetz; Tannin A Schmidt; Antoine Dufour Journal: Front Pharmacol Date: 2021-12-07 Impact factor: 5.810